MedTrace Logo

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

NCT07403370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-05-19

No results posted yet for this study

Summary

Olanzapine is an effective antiemetic agent for preventing highly emetogenic regimens-induced nausea and vomiting (HER-INV) in patients receiving highly emetogenic regimens (HER). The optimal dose remains debated, with the standard 10 mg dose often causing significant daytime sedation. Recent evidence suggests that lower doses (2.5 mg and 5 mg) may offer comparable efficacy with improved tolerability. However, no head-to-head randomized controlled trials (RCTs) directly compare all three doses.

Conditions

Interventions

DRUG

Olanzapine (dose comparison: 2.5 mg, 5 mg, 10 mg)

Olanzapine (dose: 2.5 mg) vs. olanzapine (dose: 5 mg) vs. olanzapine (dose: 10 mg)

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-18
Primary Completion
2026-02-15
Completion
2026-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07403370 on ClinicalTrials.gov